Quantcast

Latest TNF inhibitor Stories

2014-03-21 23:03:40

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html. Albany, NY (PRWEB) March 21, 2014 The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the...

2014-03-20 08:29:06

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. "Since treatment options are limited, we welcome research that evaluates new options for patients suffering...

2014-02-19 08:31:28

Proceeds Bring Series B to CHF 44.9 Million ZURICH-SCHLIEREN, Switzerland, Feb. 19, 2014 /PRNewswire/ -- Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future potentially increasing the total amount of this financing round to CHF 58.9 million. The additional financing will primarily...